Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
주식 순위 #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
주가
$17.15
마지막 동기화: 2026-08-03
시가총액
$6.51M
변동 (1일)
9.80%
변동 (1년)
289.77%
국가
US
거래 Galera Therapeutics, Inc. (GRTX)

카테고리

Galera Therapeutics, Inc. (GRTX)의 P/S 비율
August 2026 기준 P/S 비율 TTM: 0.00
Galera Therapeutics, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0.00입니다. 2023년 말 기준 P/S 비율은 0.00였습니다.
Galera Therapeutics, Inc.의 P/S 비율 기록 (2017 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE